Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, August 2000, p. 2214-2216, Vol. 44, No. 8
Department of
Endoscopy1 and Third Department of
Internal Medicine,4 Hokkaido University School
of Medicine, Sapporo, and Third Department of Internal
Medicine, Kyoto Prefectural University of Medicine,
Kyoto,3 Japan, and Department of
Medicine, Baylor College of Medicine, Veterans Affairs Medical Center,
Houston, Texas2
Received 20 January 2000/Returned for modification 10 May
2000/Accepted 18 May 2000
The patterns of antibiotic resistance in Helicobacter
pylori were assessed in two different regions in Japan. Overall,
prevalences of resistance to metronidazole and clarithromycin were 12.4 and 12.9%, respectively. While there was no difference in
clarithromycin resistance, the prevalence of metronidazole resistance
was significantly higher in Kyoto (23.8%) than in Sapporo (8.1%).
From 1996 to 1999, the prevalence of metronidazole resistance did not
change but the prevalence of clarithromycin resistance doubled (from
9.1 to 18.7%).
Helicobacter pylori
infection is now established as a major cause of peptic ulcer disease
(5, 10), and it has been shown that successful treatment of
H. pylori infection results in the cure of peptic ulcer
diseases (6, 17). Although the standard treatment for
H. pylori-related disease is a combination of two or more
antimicrobial agents and acid suppression, no therapy is universally
successful. Poor patient compliance with treatment and the presence of
resistant organisms are thought to be the most important
variables predicting a low cure rate. Antibiotic resistance in
H. pylori is a growing problem. The reported
frequencies of resistance to the antibiotics have varied widely between
geographic regions and among subgroups within a study population
(1, 3, 4, 7, 14-16, 18). For example, metronidazole
resistance varies from 10 to 80% among geographic regions (3, 4,
7, 15, 18). Knowledge of the prevalence of antibiotic resistance of H. pylori in any area is important because treatment
for H. pylori infection is often started on an
empirical basis. If the infecting strain is resistant, therapy is
likely to be unsuccessful. Macrolide use is widespread in Japan,
suggesting that resistance to clarithromycin may be prevalent. The aim
of this study was to assess the frequencies of primary resistance to
metronidazole, clarithromycin, and amoxicillin among H. pylori isolates from two different metropolitan hospitals in
Japan.
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Regional Differences in Metronidazole Resistance and Increasing
Clarithromycin Resistance among Helicobacter
pylori Isolates from Japan
ABSTRACT
Top
Abstract
Text
References
TEXT
Top
Abstract
Text
References
TABLE 1.
Comparison of antibiotic resistance of H. pylori isolates between Sapporo and Kyoto
H. pylori isolates were obtained from Hokkaido
University Hospital (Sapporo) and Kyoto Prefectural University of
Medicine Hospital (Kyoto) between January 1996 and February 1999. Sapporo is located in Hokkaido, the northern island of Japan, and Kyoto is centrally located in Honshu, the main island of Japan. The population of each city is more than one million people. The population we studied was genetically homogeneous Japanese (so-called modern "Yamato" Japanese). Duodenal ulcers were identified endoscopically, and gastritis was defined as histologic gastritis with no peptic ulcers, gastric cancer, or any esophageal diseases (e.g.,
gastroesophageal reflux disease or esophageal cancer). No subjects had
received treatment for H. pylori infection. Informed
consent was obtained from all patients, and the protocol was approved
by each local ethics committee. Gastric mucosal biopsy specimens
obtained from the patients were used to isolate H. pylori (multicolonies) as described previously (12).
All stock cultures were maintained at 
80°C in brain heart infusion
broth (Difco, Detroit, Mich.) supplemented with 20% glycerol
(Sigma Chemical Co., St. Louis, Mo.).
The recovered H. pylori isolates from the stock cultures were tested for susceptibilities to metronidazole, clarithromycin, and amoxicillin by a serial two-fold agar dilution method (11) with a minor modification. Briefly, agar dilution plates were prepared using Mueller-Hinton agar as the base medium. Aged sheep blood (2 weeks old) was added to the Mueller-Hinton base medium at a concentration of 5%. The ranges for the antibiotics were the following: metronidazole, 1 to 256 µg; and clarithromycin and amoxicillin, 0.5 to 16 µg. Fresh H. pylori isolates (cultured for 2 to 3 days) were prepared in sterile saline and adjusted to an optical density at 625 nm of 0.38 to 0.4. Using a Steers-type replicating device, 1 to 5 µl of the adjusted inocula was delivered to the agar plates. All plates were incubated under CampyPak Plus conditions (Becton Dickinson BBL, Cockeysville, Md.) at 37°C for 3 days. The MIC was defined as the lowest concentration of antibiotic that completely inhibited the growth of the inoculum. H. pylori isolates were considered resistant when the MIC of metronidazole was >8 µg/ml (12) and the MIC for clarithromycin was >1 µg/ml (9). Breakpoints for amoxicillin have not been established, and the data are presented in relation to the MICs. Metronidazole-resistant H. pylori ATCC 43504 was used as a quality-control organism. Any test in which the MIC for the quality-control organism was outside the approved range (64 to 256 µg of metronidazole/ml) was completely discarded.
We examined 388 H. pylori isolates: 283 strains from Sapporo, Hokkaido (53 from patients with histological gastritis only [gastritis], 100 from patients with gastric ulcer, 93 from patients with duodenal ulcer, and 37 from patients with gastric cancer), and 105 strains from Kyoto, Honshu (27 from patients with gastritis, 39 from patients with gastric ulcer, 25 from patients with duodenal ulcer, and 14 from patients with gastric cancer). Patients from Sapporo consisted of 180 men and 103 women (median age, 50 years; range, 21 to 85 years), and patients from Kyoto consisted of 67 men and 38 women (median age, 53 years; range, 21 to 84 years). There were no correlations between gender or age and any disease group in either Sapporo or Kyoto.
Overall, the rates of primary resistance to metronidazole and
clarithromycin were 12.4 and 12.9%, respectively (Table 1). Dual metronidazole and clarithromycin resistance was present in 2.3%
of isolates (9 of 388) (5 from Sapporo and 4 from Kyoto). For all
isolates, MICs of amoxicillin were 
0.5 µg/ml. The prevalence of
metronidazole resistance was significantly higher in Kyoto than in
Sapporo (23.8 versus 8.1%; P < 0.05). There was no
difference in the prevalence of clarithromycin resistance between the
two areas. There were no significant differences in metronidazole and
clarithromycin resistance rates according to age, gender, and disease
presentation among the patients. However, the prevalence of primary
metronidazole resistance increased recently in Sapporo, and
there was a marked increase in the prevalence of primary metronidazole resistance in 1997 in Kyoto (Table
2). Interestingly, the prevalence of
primary clarithromycin resistance increased in both regions. Overall,
the prevalence of clarithromycin doubled (9.1 to 18.7%) during
the study period (P < 0.05) (Table 2).
|
Antimicrobial resistance of H. pylori is thought to be the consequence of antibiotic consumption in the community (8). In Japan, the government (The Ministry of Health and Welfare) has not allowed the use of antibiotics for H. pylori therapies in the study period. For this reason, Japan should be the ideal country for examining primary resistance rates of H. pylori to various antibiotics. The primary resistances to clarithromycin and metronidazole observed in this study are probably due to the previous use of these antimicrobial agents for other infections. The reported prevalence of primary resistance of H. pylori to clarithromycin varies between 1 and 17% in other countries (1, 14, 16, 18). The prevalence of clarithromycin resistance in H. pylori was high and increasing despite the fact that H. pylori therapy is not used in Japan. Clarithromycin was developed in Japan and is very popular for the treatment of respiratory tract infections. Reducing the use of clarithromycin might reduce the prevalence of clarithromycin resistance. For example, a 50% decrease in macrolide consumption between 1988 and 1992 in Finland led to a decrease in resistance of group A streptococci from 19 to 9%, but after a 5-year lag phase (13).
The overall prevalence of metronidazole resistance in H. pylori (12.4%) was within the range reported from other countries (less than 10% to greater than to 80% between geographic regions) (2, 3, 4, 7, 14). Metronidazole-resistant H. pylori isolates were significantly more prevalent in Kyoto than in Sapporo (23.8 versus 8.1%; P < 0.05). Our preliminary observation for multicenter analysis indicates that there is a north-to-south gradient in metronidazole resistance in Japan. There was a similar tendency for macrolide resistance rates in Europe, high in the south and low in the north, possibly due to a difference in consumption of the antibiotic (8). Debets-Ossenkopp et al. examined metronidazole resistance in three different parts of The Netherlands and found that resistance rates were different (south, 11.6%; west, 24.3%) although the rates of consumption of metronidazole were similar (2). There was no significant difference in clarithromycin and metronidazole resistance in relation to age, sex, or disease presentation in this study. Other studies have shown a higher frequency of metronidazole-resistant isolates from women, possibly due to the use of this agent for the treatment of genitourinary tract infections.
In summary, we found regional differences in metronidazole resistance and increasing clarithromycin resistance among H. pylori isolates from Japan. These results suggest that differential factors may be involved in the development of metronidazole resistance in the two areas. In addition, the high rate of clarithromycin resistance suggests that the effectiveness of clarithromycin-based anti-H. pylori therapies may soon be compromised in Japan.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Rm. 3A-320 (111D), Veterans Affairs Medical Center, 2002 Holcombe Blvd., Houston, TX 77030. Phone: (713) 794-7276. Fax: (713) 795-4471. E-mail: dkwon{at}bcm.tmc.edu.
Present address: Department of Medicine, Samsung Medical Center,
Sungkyunkwan University School of Medicine, Seoul, Korea.
| |
REFERENCES |
|---|
|
Top
Abstract
Text
References
|
|---|
| 1. |
Adamek, R. J.,
S. Suerbaum,
B. Pfaffenbach, and W. Opferkuch.
1998.
Primary and acquired Helicobacter pylori resistance to clarithromycin, metronidazole, and amoxicillin influence on treatment outcome.
Am. J. Gastroenterol.
93:386-389[Medline].
|
| 2. |
Debets-Ossenkopp, Y. J.,
A. J. Herscheid,
R. G. Pot,
E. J. Kuipers,
J. G. Kusters, and C. M. Vandenbroucke-Grauls.
1999.
Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxycillin, tetracycline and trovafloxacin in The Netherlands.
J. Antimicrob. Chemother.
43:511-515 |
| 3. | European Study Group on Antibiotic Susceptibility of Helicobacter pylori. 1992. Results of a multicentre European survey in 1991 of metronidazole resistance in Helicobacter pylori. Eur. J. Clin. Microbiol. Infect. Dis. 11:777-781[CrossRef][Medline]. |
| 4. | Glupczynski, Y., A. Burette, E. De Koster, J. F. Nyst, M. Deltenre, S. Cadranel, L. Bourdeaux, and D. De Vos. 1990. Metronidazole resistance in Helicobacter pylori. Lancet 335:976-977[Medline]. |
| 5. | Graham, D. Y. 1997. Helicobacter pylori infection in the pathogenesis of duodenal ulcer and gastric cancer: a model. Gastroenterology 113:1983-1991[CrossRef][Medline]. |
| 6. | Graham, D. Y., and M. F. Go. 1993. Helicobacter pylori: current status. Gastroenterology 105:279-282[Medline]. |
| 7. | Ling, T. K., A. F. Cheng, J. J. Sung, P. Y. Yiu, and S. S. Chung. 1996. An increase in Helicobacter pylori strains resistant to metronidazole: a five-year study. Helicobacter 1:57-61[Medline]. (Erratum, 1:129.) |
| 8. | Megraud, F. 1998. Epidemiology and mechanism of antibiotic resistance in Helicobacter pylori. Gastroenterology 115:1278-1282[CrossRef][Medline]. |
| 9. |
Megraud, F.,
N. Lehn,
T. Lind,
E. Bayerdorffer,
C. O'Morain,
R. Spiller,
P. Unge,
S. V. van Zanten,
M. Wrangstadh, and C. F. Burman.
1999.
Antimicrobial susceptibility testing of Helicobacter pylori in a large multicenter trial: the MACH 2 study.
Antimicrob. Agents Chemother.
43:2747-2752 |
| 10. |
National Institutes of Health Consensus Conference.
1994.
Helicobacter pylori in peptic ulcer disease. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease.
JAMA
272:65-69 |
| 11. | NCCLS. 1999. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A4. NCCLS, Wayne, Pa. |
| 12. | Osato, M. S., R. Reddy, and D. Y. Graham. 1999. Metronidazole and clarithromycin resistance amongst Helicobacter pylori isolates from a large metropolitan hospital in the United States. Int. J. Antimicrob. Agents 12:341-347[CrossRef][Medline]. |
| 13. |
Seppala, H.,
T. Klaukka,
J. Vuopio-Varkila,
A. Muotiala,
H. Helenius,
K. Lager, and P. Huovinen.
1997.
The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. Finnish Study Group for Antimicrobial Resistance.
N. Engl. J. Med.
337:441-446 |
| 14. | Vakil, N., B. Hahn, and D. McSorley. 1998. Clarithromycin-resistant Helicobacter pylori in patients with duodenal ulcer in the United States. Am. J. Gastroenterol. 93:1432-1435[CrossRef][Medline]. |
| 15. | van Zwet, A. A., W. A. de Boer, P. M. Schneeberger, J. Weel, A. R. Jansz, and J. C. Thijs. 1996. Prevalence of primary Helicobacter pylori resistance to metronidazole and clarithromycin in The Netherlands. Eur. J. Clin. Microbiol. Infect. Dis. 15:861-864[CrossRef][Medline]. |
| 16. | Vasquez, A., Y. Valdez, R. H. Gilman, J. J. McDonald, T. U. Westblom, D. Berg, H. Mayta, and V. Gutierrez. 1996. Metronidazole and clarithromycin resistance in Helicobacter pylori determined by measuring MICs of antimicrobial agents in color indicator egg yolk agar in a miniwell format. The Gastrointestinal Physiology Working Group of Universidad Peruana Cayetano Heredia and the Johns Hopkins University. J. Clin. Microbiol. 34:1232-1234[Abstract]. |
| 17. |
Walsh, J. H., and W. L. Peterson.
1995.
The treatment of Helicobacter pylori infection in the management of peptic ulcer disease.
N. Engl. J. Med.
333:984-991 |
| 18. | Wolle, K., M. Nilius, A. Leodolter, W. A. Muller, P. Malfertheiner, and W. Konig. 1998. Prevalence of Helicobacter pylori resistance to several antimicrobial agents in a region of Germany. Eur. J. Clin. Microbiol. Infect. Dis. 17:519-521[Medline]. |
Antimicrobial Agents and Chemotherapy, August 2000, p. 2214-2216, Vol. 44, No. 8
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Boyanova, L., Ilieva, J., Gergova, G., Spassova, Z., Nikolov, R., Davidkov, L., Evstatiev, I., Kamburov, V., Katsarov, N., Mitov, I.
(2009). Evaluation of clinical and socio-demographic risk factors for antibacterial resistance of Helicobacter pylori in Bulgaria. J Med Microbiol
58: 94-100
[Abstract] [Full Text] -
Hamashima, C., Shibuya, D., Yamazaki, H., Inoue, K., Fukao, A., Saito, H., Sobue, T.
(2008). The Japanese Guidelines for Gastric Cancer Screening. Jpn J Clin Oncol
38: 259-267
[Abstract] [Full Text] -
Kobayashi, I., Murakami, K., Kato, M., Kato, S., Azuma, T., Takahashi, S., Uemura, N., Katsuyama, T., Fukuda, Y., Haruma, K., Nasu, M., Fujioka, T.
(2007). Changing Antimicrobial Susceptibility Epidemiology of Helicobacter pylori Strains in Japan between 2002 and 2005. J. Clin. Microbiol.
45: 4006-4010
[Abstract] [Full Text] -
Megraud, F.
(2007). Helicobacter pylori and antibiotic resistance. Gut
56: 1502-1502
[Full Text] -
Noguchi, N., Rimbara, E., Kato, A., Tanaka, A., Tokunaga, K., Kawai, T., Takahashi, S., Sasatsu, M.
(2007). Detection of mixed clarithromycin-resistant and -susceptible Helicobacter pylori using nested PCR and direct sequencing of DNA extracted from faeces. J Med Microbiol
56: 1174-1180
[Abstract] [Full Text] -
Miernyk, K. M., Bruden, D. L., Bruce, M. G., McMahon, B. J., Hennessy, T. W., Peters, H. V., Hurlburt, D. A., Sacco, F., Parkinson, A. J.
(2007). Dynamics of Helicobacter pylori-Specific Immunoglobulin G for 2 Years after Successful Eradication of Helicobacter pylori Infection in an American Indian and Alaska Native Population. CVI
14: 85-86
[Abstract] [Full Text] -
Minami, M., Ando, T., Hashikawa, S.-n., Torii, K., Hasegawa, T., Israel, D. A., Ina, K., Kusugami, K., Goto, H., Ohta, M.
(2004). Effect of Glycine on Helicobacter pylori In Vitro. Antimicrob. Agents Chemother.
48: 3782-3788
[Abstract] [Full Text] -
Fujimura, S., Kato, S., Iinuma, K., Watanabe, A.
(2004). In vitro activity of fluoroquinolone and the gyrA gene mutation in Helicobacter pylori strains isolated from children. J Med Microbiol
53: 1019-1022
[Abstract] [Full Text] -
Megraud, F
(2004). H pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut
53: 1374-1384
[Full Text] -
Kwon, D. H., Dore, M. P., Kim, J. J., Kato, M., Lee, M., Wu, J. Y., Graham, D. Y.
(2003). High-Level {beta}-Lactam Resistance Associated with Acquired Multidrug Resistance in Helicobacter pylori. Antimicrob. Agents Chemother.
47: 2169-2178
[Abstract] [Full Text] -
Panthel, K., Faller, G., Haas, R.
(2003). Colonization of C57BL/6J and BALB/c Wild-Type and Knockout Mice with Helicobacter pylori: Effect of Vaccination and Implications for Innate and Acquired Immunity. Infect. Immun.
71: 794-800
[Abstract] [Full Text] -
Panthel, K., Jechlinger, W., Matis, A., Rohde, M., Szostak, M., Lubitz, W., Haas, R.
(2003). Generation of Helicobacter pylori Ghosts by PhiX Protein E-Mediated Inactivation and Their Evaluation as Vaccine Candidates. Infect. Immun.
71: 109-116
[Abstract] [Full Text] -
Meyer, J. M., Silliman, N. P., Wang, W., Siepman, N. Y., Sugg, J. E., Morris, D., Zhang, J., Bhattacharyya, H., King, E. C., Hopkins, R. J.
(2002). Risk Factors for Helicobacter pylori Resistance in the United States: The Surveillance of H. pylori Antimicrobial Resistance Partnership (SHARP) Study, 1993-1999. ANN INTERN MED
136: 13-24
[Abstract] [Full Text]
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»